Skip to content

A single-center, randomized, prospective clinical study of Azisartan versus valsartan in the treatment of post-infarction ventricular remodeling in patients with diabetes after STEMI

A single-center, randomized, prospective clinical study of Azisartan versus valsartan in the treatment of post-infarction ventricular remodeling in patients with diabetes after STEMI

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068678
Enrollment
Unknown
Registered
2023-02-27
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Azisartan:Azisartan 20-40mg orally
valsartan:valsartan80-160mg orally

Sponsors

The People’s Hospital of Liaoning Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) According to Type 1 myocardial infarction in the Diagnostic and Therapeutic Guidelines for Acute ST-Segment Elevation Myocardial Infarction (2019 edition) of the Cardiovascular Society of the Chinese Medical Association, that is, spontaneous myocardial infarction.2) Emergency coronary intervention was performed.3) The patient voluntarily participated in the experiment, understood and signed the informed consent.4) Subjects can complete the study according to the regulations.Relatives of employees or researchers at the center.

Exclusion criteria

Exclusion criteria: 1) Patients who met the diagnosis of STEMI but did not undergo emergency PCI for various reasons;2) Patients without stent implantation during PCI;3) Patients with acute and chronic infectious diseases;4) Patients with cardiogenic shock;5) Patients with hypovolemic shock;6) Patients with a history of myocardial infarction;7) Patients with heart failure caused by various causes;8) Patients with liver and kidney failure;9) Patients with tumor;10) Patients with rheumatic immune system disease;11) Patients with valvular heart disease;12) Patients with persistent and permanent atrial fibrillation;13) Any situation in which the investigator deems it inappropriate to participate in the study;14) The patients in the study were relatives of employees or researchers at the center.

Design outcomes

Primary

MeasureTime frame
Transthoracic echocardiography;cardiac magnetic resonance;

Countries

China

Contacts

Public Contactduanna

The People’s Hospital of Liaoning Province

83813907@qq.com17702487660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026